- Home
- AUPH vs XERS Comparison
AUPH vs XERS Comparison
Compare AUPH & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUPH
- XERS
- Stock Information
- Founded
- AUPH 1993
- XERS 2005
- Country
- AUPH Canada
- XERS United States
- Employees
- AUPH N/A
- XERS N/A
- Industry
- AUPH Biotechnology: Pharmaceutical Preparations
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- AUPH Health Care
- XERS Health Care
- Exchange
- AUPH Nasdaq
- XERS Nasdaq
- Market Cap
- AUPH 1.4B
- XERS 1.3B
- IPO Year
- AUPH 1999
- XERS 2018
- Fundamental
- Price
- AUPH $12.22
- XERS $7.78
- Analyst Decision
- AUPH Strong Buy
- XERS Strong Buy
- Analyst Count
- AUPH 4
- XERS 7
- Target Price
- AUPH $12.25
- XERS $8.00
- AVG Volume (30 Days)
- AUPH 1.7M
- XERS 2.1M
- Earning Date
- AUPH 11-06-2025
- XERS 11-07-2025
- Dividend Yield
- AUPH N/A
- XERS N/A
- EPS Growth
- AUPH N/A
- XERS N/A
- EPS
- AUPH 0.42
- XERS N/A
- Revenue
- AUPH $260,111,000.00
- XERS $246,025,000.00
- Revenue This Year
- AUPH $16.92
- XERS $43.89
- Revenue Next Year
- AUPH $14.29
- XERS $20.40
- P/E Ratio
- AUPH $29.10
- XERS N/A
- Revenue Growth
- AUPH 25.59
- XERS 35.62
- 52 Week Low
- AUPH $6.42
- XERS $2.60
- 52 Week High
- AUPH $12.82
- XERS $8.03
- Technical
- Relative Strength Index (RSI)
- AUPH 61.79
- XERS 67.70
- Support Level
- AUPH $11.57
- XERS $7.56
- Resistance Level
- AUPH $12.82
- XERS $8.03
- Average True Range (ATR)
- AUPH 0.36
- XERS 0.23
- MACD
- AUPH -0.10
- XERS -0.10
- Stochastic Oscillator
- AUPH 52.08
- XERS 55.77
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).